Breakthrough Flu Protection: Single Dose Could Last All Season
London, Wednesday, 24 June 2026.
RQ Bio secures $115 million to revolutionize flu prevention with a long-acting antibody, RQB01, offering full-season protection from a single dose. This could transform healthcare by reducing outbreaks and boosting productivity, especially for high-risk groups.
A New Era in Influenza Prevention
On 24 June 2026, London-based biotechnology company RQ Bio announced a landmark $115 million (£85.5 million) Series A financing round, marking a significant milestone in the development of long-acting antibody therapies for infectious diseases [1]. The funding, led by Frazier Life Sciences, will accelerate the clinical advancement of RQB01, a novel monoclonal antibody designed to provide full-season protection against influenza with a single administration [1]. This breakthrough could redefine influenza prevention strategies, particularly for high-risk and immunocompromised populations who may not respond adequately to traditional vaccines [1][2].
Investor Confidence in Next-Generation Therapies
The oversubscribed Series A round reflects growing investor confidence in RQ Bio’s innovative approach to infectious disease prevention. Alongside lead investor Frazier Life Sciences, new investors EQT Life Sciences, Forbion, Monograph, and Wellington Management joined founding investors LifeArc Ventures, Oxford Science Enterprises, and the University of Oxford in backing the company [1][2]. The substantial capital infusion underscores the potential of RQB01 to address a critical gap in public health, particularly as influenza continues to pose a persistent threat to vulnerable populations [1].
Leadership and Scientific Innovation
RQ Bio, founded in 2021, has rapidly advanced its lead program, RQB01, into Investigational New Drug (IND)-enabling studies [2]. The therapy leverages a dual mechanism of action, targeting conserved epitopes of the influenza virus that are resilient to seasonal variation [1]. This approach aims to deliver broad strain coverage, potent neutralizing activity, and an extended duration of action, potentially offering protection for an entire flu season with a single dose [1]. Christian S. Schade, former CEO of Halda Therapeutics (acquired by Johnson & Johnson for $3.05 billion in December 2025), has been appointed as Executive Chairman to guide the company through this pivotal phase [2].
Addressing Unmet Needs in Influenza Prevention
Influenza remains a significant public health challenge, with annual epidemics causing substantial morbidity, mortality, and economic burden. The World Health Organization estimates that seasonal influenza results in 3 to 5 million cases of severe illness and 290,000 to 650,000 respiratory deaths globally each year [GPT]. Traditional vaccines, while effective for many, often fall short for immunocompromised individuals and other high-risk groups, leaving them vulnerable to severe outcomes [1]. RQB01 is specifically designed to address this unmet need by providing reliable, long-lasting protection for those who cannot rely on vaccination alone [1][2].
The Road Ahead: Clinical Development and Beyond
With the Series A funding secured, RQ Bio is poised to advance RQB01 into clinical development, with plans to initiate human trials in 2027 [1][2]. The company’s focus on high-risk and immunocompromised populations aligns with global health priorities, particularly as antimicrobial resistance and emerging infectious diseases continue to challenge healthcare systems [GPT]. Clare Terlouw, Managing Partner at LifeArc Ventures, highlighted the significance of the funding: “The oversubscribed Series A is a testament to the scientific excellence and focused drive of the RQ team and is a great example of first-class British science being backed for success on the global stage” [2].
Investor Perspectives on RQ Bio’s Potential
Investors in RQ Bio have expressed strong confidence in the company’s scientific foundation and market potential. Joe Cabral, Partner at Frazier Life Sciences, noted: “RQ Bio has a strong team with extensive experience in infectious disease and what we believe is a highly innovative approach to influenza prevention. We believe RQB01 possesses several differentiated attributes that will translate to efficacious, season-long prevention of flu in an attractive product format” [1]. The therapy’s dual mechanism of action, broad strain coverage, and extended duration of action position it as a potential game-changer in the $6.5 billion global influenza vaccine market [GPT].